Genetic testing service deCODEme shutting down in wake of Amgen/deCODE deal

Sequencing Money x

The big biotech news of the day is the $415 million sale of deCODE Genetics to Amgen. Coverage of the deal is everywhere, including a typically excellent overview from Matthew Herper of Forbes.

Meanwhile, it’s quite likely that the sale to Amgen will usher in the final chapter of deCODE’s long-running direct-to-consumer (DTC) genetic testing business, deCODEme. deCODEme’s sole product – thedeCODEme Complete Scan – covers 47 conditions and traits and retails for a whopping $1,100.

Update 12/12: As predicted, Amgen has now confirmed that deCODEme will be shutting down. An Amgen spokesperson confirmed to Pharmacogenomics Reporter that “Amgen does not intend to continue offering genomic screening tests to the public and healthcare providers. This is not a core part of Amgen’s business interest in Decode…Employees and resources focused on this area will be realigned with other priorities and projects.”

View the original article here: Implications of Amgen/deCODE Deal for Genetic Testing Consumers

Outbreak Daily Digest
Biotech Facts & Fallacies
Talking Biotech
Genetics Unzipped
Infographic: The evolutionary history of the COVID-19 coronavirus

Infographic: The evolutionary history of the COVID-19 coronavirus

Reuters analysed over 185,000 genome samples from the Global Initiative on Sharing All influenza Data (GISAID), the largest database of ...

Environmental Working Group: EWG challenges safety of GMOs, food pesticide residues

Known by some as the "Environmental Worrying Group," EWG lobbies ...
m hansen

Michael Hansen: Architect of Consumers Union ongoing anti-GMO campaign

Michael K. Hansen (born 1956) is thought by critics to be ...
News on human & agricultural genetics and biotechnology delivered to your inbox.
glp menu logo outlined

Newsletter Subscription

Optional. Mail on special occasions.
Send this to a friend